Breaking News
January 19, 2018 - ‘You’re Old and You Need Tests’: What We Heard This Week
January 19, 2018 - Egg-preserving hysterectomy raises heart risks later: study
January 19, 2018 - GA-map Dysbiosis Test identifies IBS patients who respond to FODMAP diet, study shows
January 19, 2018 - Study explores mortality and health-related habits in former elite athletes and their brothers
January 19, 2018 - New biodegradable sensors could assist doctors
January 19, 2018 - Modular gene enhancers may be suitable target in treatment of blood cancer
January 18, 2018 - New precision medicine trial for metastatic pancreatic cancer
January 18, 2018 - Shire Receives FDA Breakthrough Therapy Designation for Maribavir, an Investigational Treatment for Cytomegalovirus (CMV) Infection in Transplant Patients
January 18, 2018 - Pre-Existing Patient-Valve Mismatch Trips Up ViV Implant
January 18, 2018 - Adolescents: health risks and solutions
January 18, 2018 - US woman delivers baby from embryo frozen for 24 years
January 18, 2018 - Study identifies new target for treatment of depression
January 18, 2018 - LJI study reveals key player that promotes skin inflammation in atopic dermatitis
January 18, 2018 - Study devises efficient and economical strategy to screen breast and ovarian cancer gene mutations
January 18, 2018 - Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla (AG200-15) for the Prevention of Pregnancy
January 18, 2018 - Gene Therapy for Inherited Retinal Dystrophy Gets FDA Clearance
January 18, 2018 - Researchers identify a new chemical pathway that helps the brain detect sweet, savory and bitter flavors
January 18, 2018 - IBV develops platform that helps companies to diagnose wellbeing of their workforce
January 18, 2018 - Study to test new precision medicine approach for metastatic pancreatic cancer
January 18, 2018 - World’s first vaccine relieves grass pollen allergy symptoms by at least 25%, study shows
January 18, 2018 - FDA Approves New Indication for Gilotrif (afatinib) in EGFR Mutation-Positive NSCLC
January 18, 2018 - Oncologists Dish on Top Issues for 2018
January 18, 2018 - Researchers identify new potential drug target for Huntington’s disease
January 18, 2018 - Metrohm USA welcomes employees to new headquarters in Florida
January 18, 2018 - Human waste remains main source of fecal pollution in the river Danube
January 18, 2018 - Expert discusses how to stay healthy during flu season
January 18, 2018 - New biomaterials-based system improves T-cell production
January 18, 2018 - Novel gene expression analysis technique can accurately and quickly measure RNA
January 18, 2018 - Grandparents Help Shape Kids’ Views on Aging
January 18, 2018 - Absolutely Zero Stent Thrombosis at 5 Years With Bioabsorbable MiStent
January 18, 2018 - Safe Sleep for Babies | VitalSigns
January 18, 2018 - Pfizer to launch own little white pill
January 18, 2018 - Aged garlic extract may help obese people fight against inflammation, study shows
January 18, 2018 - Sex steroid hormone fluctuations may have direct effects on eye physiology and AMD
January 18, 2018 - Patients with monoclonal gammopathy at risk of developing cancer even after 30 years
January 18, 2018 - Researchers reveal potential of multivalent antibodies for HIV prevention, treatment and cure
January 18, 2018 - Dying cancer patients receiving assisted hydration live longer
January 18, 2018 - Potential male birth control pill could be developed from arrow poison
January 18, 2018 - Research reveals cost-effectiveness of whole-population screening for breast, ovarian cancer gene mutations
January 18, 2018 - Genes involved in spinal cord repair of lamprey also present in mammals, study reveals
January 18, 2018 - Researchers unravel key molecular mechanism of autoimmune and inflammatory diseases
January 18, 2018 - The State of the Drug Discovery Nation Unveiled as New Report Provides Vital Insights for the Development of New Medicines
January 18, 2018 - Dutch Study Links Implants to Increased Breast-ALCL Risk
January 18, 2018 - Five addiction experts weigh in on future of opioid crisis. Their forecast: grim
January 18, 2018 - EXD2 enzyme facilitates protein production in mitochondria
January 18, 2018 - Kessler Foundation wins $735,000 grant for training rehabilitation researchers
January 18, 2018 - Researchers find new way to halt growth of breast cancer cells
January 18, 2018 - Cantex Pharmaceuticals, Inc. Announces FDA Orphan Drug Designation Has Been Granted to CX-01 for Treatment of Acute Myeloid Leukemia
January 18, 2018 - Civilians Now Getting Flu-Like Illness Afflicting Troops
January 18, 2018 - Discovery brings stem cell therapy for eye disease closer to the clinic
January 18, 2018 - Guts of surfers more likely to be colonized by antibiotic-resistant bacteria, study reveals
January 18, 2018 - Bacteria linked to periodontitis may play role in onset of cancer
January 18, 2018 - Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea
January 18, 2018 - Early Menarche, Menopause Tied to Higher CVD Risk
January 18, 2018 - Pioneering new technique could boost understanding of causes of heart disease
January 18, 2018 - New brain imaging techniques show how infants’ brains process ‘touch’
January 18, 2018 - GSK Receives FDA Approval for Expanded Indication for Fluarix Quadrivalent (Influenza Vaccine) for Persons 6 Months and Older
January 18, 2018 - Blood Markers Point to Maladaptive LV Remodeling
January 18, 2018 - Effect of gut bacteria on specific immune cells underlies persistent liver inflammation
January 18, 2018 - Study reveals new diabetes gene in families with rare blood sugar conditions
January 18, 2018 - Fewer Hospitals Closed After Obamacare Expanded Medicaid
January 18, 2018 - At-Home Breath Training Improves Asthma Quality of Life
January 18, 2018 - Obesity can add five weeks of asthma symptoms per year in preschoolers
January 18, 2018 - Neuronal loss is very limited in Alzheimer’s disease, shows new study
January 18, 2018 - A new strategy proposed for drug discovery
January 17, 2018 - Lactation May Lower T2D Risk in Younger Women
January 17, 2018 - New Atopic Dermatitis Yardstick provides practical guidance and management insights
January 17, 2018 - New biodegradable pressure sensor could help monitor serious health conditions
January 17, 2018 - HSS orders Sectra’s 3D pre-operative planning solution for improving patient outcomes
January 17, 2018 - Study identifies six new genes regions associated with diabetes
January 17, 2018 - Women do not receive timely diagnosis for heart disease
January 17, 2018 - AbbVie’s Upadacitinib Shows Positive Results as Monotherapy in Phase 3 Rheumatoid Arthritis Study, Meeting All Primary and Key Secondary Endpoints
January 17, 2018 - Should President Trump’s Physical Include a Cognitive Screen?
January 17, 2018 - Could gene therapy someday eliminate HIV?
January 17, 2018 - Researchers identify new anti-inflammatory drug target
January 17, 2018 - Loxo Oncology Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancers
January 17, 2018 - Trunk Imaging Tied to Higher Nephrectomy Risk
January 17, 2018 - Campaigners incensed at failings in Africa AIDS war
January 17, 2018 - Research opens door to development of new treatment for type 2 diabetes
January 17, 2018 - Uniqsis’ novel reactor system for continuous flow synthesis
CHEST: Novel Agent Boosts Quality of Life in COPD

CHEST: Novel Agent Boosts Quality of Life in COPD

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • Revefenacin, an investigational long-acting nebulized drug for chronic obstructive pulmonary disease (COPD), improved patient quality of life in two pivotal phase III placebo-controlled studies.
  • Note that revefenacin, if FDA-approved, would be the first once daily, long-acting muscarinic antagonist (LAMA) indicated for patients with COPD.

TORONTO — An investigational long-acting drug for chronic obstructive pulmonary disease (COPD), delivered by nebulizer, improved patient quality of life in two pivotal studies, researchers said here.

In a pooled analysis of the placebo-controlled phase III trials 0126 and 0127, patients reported marked improvement on two scales, the St George’s Respiratory Questionnaire (SGRQ) and COPD Assessment Test (CAT) with revefenacin treatment, according to James Donohue, MD, of the University of North Carolina in Chapel Hill, and colleagues.

On both scales, patients reported “clinically meaningful” responses to the drug in secondary analyses, Donohue reported at CHEST, the American College of Chest Physicians annual meeting.

If approved, revefenacin would be the first once daily, long-acting muscarinic antagonist (LAMA) indicated for patients with COPD, Donohue said. He told MedPage Today it would be an important addition to the armamentarium of therapy for patients who require a nebulized treatment.

“What’s unique is that it’s in a nebulizer and it’s 24 hours,” he noted.

The results of the study are “important,” commented CHEST session co-moderator Arthur Gelb, MD, of the University of California Los Angeles. “Hopefully, [the drug] will reach clinical utilization soon.”

Donohue said the FDA is expected to make a decision soon, although it’s unclear which of two tested doses will get the nod.

Gelb told MedPage Today that one advantage of revefenacin is that it would be the “only LAMA that would be inline,” which would make it more economical to use for patients admitted to hospital.

The two studies were identical, with 1,229 patients randomly assigned on a 1:1:1 basis to placebo, 88 μg of revefenacin, or 175 μg of the drug. The primary endpoints were efficacy and safety over a 12-week period, he said.

Patients in the study were well balanced across the arms in terms of demographics. About half were current smokers and a similar proportion reported a modified Medical Research Council dyspnea score of at least 2.

Patients had moderate to severe COPD with a high risk of exacerbations, with most having GOLD system scores of 2 or 3 on numerical scoring or B and C on the alphabetical scale. Participants were “very typical” of patients in a COPD trial, Donohue said.

He noted that investigators have earlier reported that the drug had beneficial effects on breathing, with “robust” and statistically significant improvements, compared with placebo, in one-second forced expiratory volume (FEV1).

Also, the rate of adverse events in the three arms was similar, with “no really clear-cut effect in [adverse events] of the higher dose.”

Aside from efficacy and safety, key secondary analyses included patient reported outcomes, at baseline and on day 85 of treatment, on the SGRQ and CAT. The researchers recorded total scores and proportion of responders.

The analysis showed that in the 0126 study, total SGRQ scores were similar for both doses, with a significant drop of about 4 points from baseline, compared with a slight but non-significant increase among those on placebo. The greatest improvement was seen on the symptom subscale.

In the 0127 study, outcomes were much the same, but a greater than expected placebo response meant that the change with the lower dose of revefenacin did not reach statistical significance.

Over both studies, patients taking the drug were about 50% more likely to reach the 4-point improvement threshold than those on placebo, with an odds ratio of 1.56 for 88-μg dose and an OR 1.53 for the 175-μg dose.

In study 0126, both doses significantly improved total scores on the CAT, but again owing to the unexpected placebo response, only the 175-μg dose had significantly better scores in the 0127 study.

In 0126, both doses were significantly associated with a clinically meaningful CAT response, but in 0127, only the higher dose was significantly better than placebo.

Taken together, the studies demonstrated “improvements in the health status” of people using revefenacin, according to Donohue.

The study was supported by Theravance Biopharma. Several co-authors are company employees.

Donohue disclosed relevant relationships with Theravance Biopharma, Mylan, and Sunovion.

Gelb disclosed no relevant relationships with industry.

2017-10-30T09:30:00-0400

Tagged with:

About author

Related Articles